Several studies performed in healthy controls, adult GH-deficient patients, and in patients with cancer (22–25) showed a higher promoter activity (and higher IGFBP3 circulating levels) in AA>AC>CC genotypes. This evidence concerns the gene IGFBP3 and cancer.